Who
Walter Klemp V
CEO and President
Company insider
Files Form 4 as: CEO and President, Moleculin Biotech; Director, Autonomix Medical; Executive Chairman, Soliton.
In numbers
- Trades disclosed
- 127
- Buys
- 8
- Sells
- 1
- Bought
- $581K
- Sold
- $170K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 11 May 2017
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —207,500 | filing |
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code F | $18K48,659 at $0.3701 | filing |
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —415,000 | filing |
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —415,000 | filing |
| 15 Oct 2026filed 16 Oct 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —207,500 at $0.00 | filing |
| 3 Sep 2026filed 8 Sep 2026 | AMIX Autonomix MedicalMedical Devices | SEC FORM 4 Code A | —13,000 | filing |
| 3 Sep 2026filed 8 Sep 2026 | AMIX Autonomix MedicalMedical Devices | SEC FORM 4 Code A | —13,000 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Bought | —533,333 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,599,999 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,599,999 | filing |
| 3 Aug 2026filed 5 Aug 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Bought | —533,333 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —360 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —360 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code F | $27588 at $3.12 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —360 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —360 | filing |
| 22 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code F | $27588 at $3.12 | filing |
| 20 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code M | —150 | filing |
| 20 Jun 2026filed 24 Jun 2026 | MBRX Moleculin BiotechBiotechnology | SEC FORM 4 Code F | $10737 at $2.88 | filing |
| 20 Jun 2026filed 24 Jun 2026 | MBRX Moleculin Biotechoption or derivative · Biotechnology | SEC FORM 4 Code M | —150 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.